“Expected Spesolimab Plasma Exposure Following Intravenous and Subcutaneous Dosing in Patients With Generalized Pustular Psoriasis”. 2024. SKIN The Journal of Cutaneous Medicine 8 (2): s359. https://doi.org/10.25251/skin.8.supp.359.